Equities

Hua Medicine

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Hua Medicine

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)3.04
  • Today's Change-0.08 / -2.56%
  • Shares traded2.12m
  • 1 Year change+106.80%
  • Beta1.7084
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Hua Medicine is an investment holding company primarily engaged in the development and commercialization of oral drug for the treatment of Type 2 diabetes. The Company is also engaged in the commercialization of HuaTangNing products. The Company’s main product pipeline dorzagliatin or HMS5552 is a glucokinase activator or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The Company mainly conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)419.81m
  • Net income in HKD1.22bn
  • Incorporated2009
  • Employees285.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cloudbreak Pharma Inc78.16m-326.97m1.91bn60.00------24.47-0.3898-0.38980.0932-3.08------1,532,549.00-------------418.33------19.44------23.40------
ImmuneOnco Biopharmaceuticls Shanghi Inc126.96m-342.81m1.98bn195.00--3.08--15.57-0.8715-0.87150.32251.490.148--3,865.48813,859.90-40.09---51.56-------270.79------0.2236--19,109.59--16.76------
Mabpharm Ltd480.14m-31.12m2.10bn383.00--18.7856.964.38-0.0076-0.00760.11640.02720.42090.46594.051,524,243.00-2.73-19.62-4.02-25.6986.40---6.48-211.590.6906-1.580.7552--196.27--38.89---12.13--
Jiangsu Recbio Technology Co Ltd12.34m-740.61m2.11bn507.00--10.29--170.98-1.55-1.550.02580.42470.006----23,246.88-36.26-31.31-64.03-37.31-----5,990.59--0.2767-100.740.8254------1.67--16.82--
Frontage Holdings Corp1.98bn29.97m2.20bn1.54k73.110.82376.991.110.01480.01480.97361.310.454560.363.971,267,645.000.69023.050.86543.6427.7832.141.526.841.221.970.28610.00-1.9020.48-92.68-46.7213.29--
Antengene Corp Ltd95.54m-258.90m2.36bn152.00--2.72--24.67-0.4166-0.41660.15381.280.06191.513.20565,309.60-16.77-48.14-19.52-53.0678.54---271.00-1,460.934.41--0.2346--36.62--45.07--259.46--
Hanx Biopharmaceuticals (Wuhan) Co Ltd-100.00bn-100.00bn2.61bn-------------------------------------------------------52.30------
Clover Biopharmaceuticals Ltd58.64m-1.03bn2.86bn243.00------48.70-0.8203-0.82030.0466-1.490.04330.054747.89195,458.50-76.07-75.37---188.1462.57---1,756.85-13,419.000.2541-------2.13---552.11---24.90--
Hua Medicine419.81m1.22bn3.21bn285.002.482.492.557.651.231.230.42531.220.24111.765.712,498,850.0069.99-21.8382.64-25.3152.55--290.30-395.247.00--0.2038--234.02---18.42---17.81--
BioDlink International Co Ltd1.21bn8.22m3.25bn604.00370.463.9235.512.690.01130.01131.671.070.72752.355.491,977,613.000.495-11.370.6586-14.8971.1073.140.6805-24.911.681.830.3519--40.7089.20192.05--27.04--
Medtide Inc-100.00bn-100.00bn3.73bn520.00--2.24----------11.73------------------------4.48--0.0335--31.31--21.00------
Visen Pharmaceuticals-100.00bn-100.00bn3.80bn54.00--3.62----------9.23----------------------------0.0014------26.98------
Qyuns Therapeutics Co Ltd362.84m-217.22m4.64bn337.00--17.88--12.77-0.978-0.9781.631.150.29034.059.141,070,314.00-17.90---28.45--72.44---61.64--1.43-23.190.7466------33.91------
Jacobio Pharmaceuticals Group Co Ltd228.07m-51.70m4.72bn211.00--4.82--20.70-0.0668-0.06680.29481.250.1547--7.97887,438.90-3.51-36.09-4.01-39.58100.0065.67-22.67-283.16----0.1415--145.13--56.64--29.33--
Data as of Feb 13 2026. Currency figures normalised to Hua Medicine's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

1.74%Per cent of shares held by top holders
HolderShares% Held
JPMorgan Asset Management (China) Co Ltd.as of 30 Jun 20256.41m0.61%
E Fund Management Co., Ltd.as of 30 Jun 20253.99m0.38%
First Trust Advisors LPas of 09 Jan 20263.69m0.35%
SSgA Funds Management, Inc.as of 08 Jan 20262.43m0.23%
Dimensional Fund Advisors LPas of 30 Nov 2025720.50k0.07%
Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025600.00k0.06%
China Universal Asset Management Co., Ltd.as of 30 Jun 2025313.50k0.03%
Truvalue Asset Management Co. Ltd.as of 30 Jun 2025183.00k0.02%
Connor, Clark & Lunn Investment Management Ltd.as of 31 Dec 202545.00k0.00%
DFA Australia Ltd.as of 31 Dec 202541.46k0.00%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.